Italia markets closed

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
7,70+0,09 (+1,18%)
Alla chiusura: 04:00PM EDT
7,61 -0,09 (-1,17%)
Dopo ore: 04:06PM EDT

MiMedx Group, Inc.

1775 West Oak Commons Court, NE
Marietta, GA 30062
United States
770 651 9100
https://www.mimedx.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno895

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. William F. Hulse IVGeneral Counsel & Chief Administrative Officer677,36kN/D1974
Dr. Robert Benjamin Stein M.D., Ph.D.President of Regenerative Medicine & Biologics Innovation639,28kN/D1951
Mr. Joseph H. CapperCEO & DirectorN/DN/D1964
Mr. Douglas C. Rice CPAChief Financial OfficerN/DN/D1966
Mr. Scott M. TurnerSenior Vice President of Operations & Procurement493,98kN/D1966
Mr. Matthew M. NotarianniHead of Investor RelationsN/DN/DN/D
Mr. Mark P. GravesSenior VP & Chief Compliance OfficerN/DN/D1966
Hilary DixonVice President of Investor Relations & Corporate Strategic CommunicationsN/DN/DN/D
Ms. Kate SurdezChief Human Resources OfficerN/DN/DN/D
Dr. David H. Mason Jr.Chief Medical OfficerN/DN/D1947
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

Governance aziendale

L'ISS Governance QualityScore di MiMedx Group, Inc. al 1 marzo 2024 è 4. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 5; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.